Abstract
Antibodies can act as a ‘magic bullet.’ Therefore, antibody–drug conjugates (ADCs) and T cell–dependent bispecific antibodies (TDBs) enable specific delivery of drugs and T cells, respectively, to tumor cells. Moreover, immune targeting represents a new concept in drug delivery systems (DDSs); for example, a lymphocyte-targeting antibody can effectively treat inflammatory autoimmune diseases and cancers. Furthermore, therapeutic antibodies have been used in clinics to treat several refractory and therapy-resistant infectious diseases. However, this approach has some disadvantages, including antibody-dependent enhancement (ADE), interstitial pneumonia, and cytokine storm. These issues may be associated with severe cases of COVID-19 infection. Here, I will review recently developed antibody DDS therapeutics and a vision for it across the fields of cancer, inflammatory autoimmune disease, and infectious disease.
